These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 17575680

  • 1. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
    Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680
    [Abstract] [Full Text] [Related]

  • 2. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee.
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [Abstract] [Full Text] [Related]

  • 3. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
    Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
    [Abstract] [Full Text] [Related]

  • 4. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T, Rehman F, Mitchison DA, Sarma GR, Reetha AM, Prabhaker R, Tuberculosis Research Centre, Indian Council of Medical Research.
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [Abstract] [Full Text] [Related]

  • 5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 6. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial.
    Jindani A, Nunn AJ, Enarson DA.
    Lancet; 2003 Oct; 364(9441):1244-51. PubMed ID: 15464185
    [Abstract] [Full Text] [Related]

  • 7. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS, Rajaram K, Sivasubramanian S, Paramasivan CN, Chandrasekar K, Kamaludeen MN, Thirithuvathas AJ, Ananthalakshmi V, Prabhakar R.
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions.
    Banu Rekha VV, Rajaram K, Kripasankar AS, Parthasarathy R, Umapathy KC, Sheikh I, Selvakumar N, Victor M, Niruparani C, Sridhar R, Jawahar MS.
    Natl Med J India; 2012 Nov; 25(4):196-200. PubMed ID: 23278775
    [Abstract] [Full Text] [Related]

  • 9. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R, Heilig CM, Tapy JM, Bozeman L, Kyle RP, Hamilton CD, Bock N, Narita M, Wing D, Hershfield E, Goldberg SV, Tuberculosis Trials Consortium.
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S, Narendran G, Venkatesan P, Iliayas S, Santhanakrishnan R, Menon PA, Padmapriyadarsini C, Ramachandran R, Chinnaiyan P, Suhadev M, Sakthivel R, Narayanan PR.
    Am J Respir Crit Care Med; 2010 Apr 01; 181(7):743-51. PubMed ID: 19965813
    [Abstract] [Full Text] [Related]

  • 11. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation.
    S Afr Med J; 1996 Aug 01; 86(8):960-5. PubMed ID: 8823423
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy.
    Int J Tuberc Lung Dis; 2001 Jan 01; 5(1):40-5. PubMed ID: 11263515
    [Abstract] [Full Text] [Related]

  • 14. Importance of rifampicin in combined daily/intermittent chemotherapy for tuberculosis.
    Felten MK.
    S Afr Med J; 1989 Jun 03; 75(11):524-6. PubMed ID: 2727841
    [Abstract] [Full Text] [Related]

  • 15. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R, Borgdorff MW, Sticht-Groh V, Rieder HL, Kawuma HJ, Bretzel G, Rüsch-Gerdes S.
    East Afr Med J; 1999 Jun 03; 76(6):307-13. PubMed ID: 10750516
    [Abstract] [Full Text] [Related]

  • 16. Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India.
    Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, Perumal V, Nair D, Chinnaiyan P, Paramasivam PK, Dhanaraj B, Santhanakrishnan RK, Navaneethapandian GP, Marimuthu MK, Kumar V, Kandasamy C, Dharuman K, Elangovan T, Narasimhan M, Rathinam S, Vadivelu G, Rathinam P, Chockalingam C, Jayabal L, Swaminathan S, Shaheed JM.
    Clin Infect Dis; 2014 Nov 15; 59(10):e142-9. PubMed ID: 25028463
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.